{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-essential-documents-during-trial-ich-e6-section-8”
},
“headline”: “SOP for Essential Documents During Trial (ICH E6 §8)”,
“description”: “This SOP defines the essential documents required to be filed and maintained during the conduct of a clinical trial, in compliance with ICH E6 §8 and global regulatory requirements, including protocols, approvals, monitoring reports, safety records, IP logs, consent forms, and training documentation.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Essential Documents During Trial (ICH E6 §8)

Purpose

The purpose of this SOP is to define the process for collecting, filing, and maintaining essential documents during the conduct of a clinical trial, as per ICH E6 §8 requirements. These documents collectively enable the evaluation of trial conduct and ensure compliance with GCP, regulatory expectations, and subject protection.

Scope

This SOP applies to sponsors, CROs, investigators, site staff, and QA responsible for maintaining essential documents in the TMF and ISF during the trial. It covers monitoring reports, approvals, informed consent forms, IP accountability logs, correspondence, safety reporting, and other trial-related documentation.

Responsibilities

• Sponsor: Ensures TMF is complete and contemporaneous.
• CRO: Maintains documents delegated by sponsor under oversight.
• Investigator: Maintains ISF and subject-level essential documents.
• CRA: Collects and files monitoring reports, logs, and site-level records.
• QA: Audits TMF and ISF to ensure inspection readiness.
• TMF Administrator: Classifies, indexes, and files documents with quality checks.

Accountability

The Head of Clinical Operations is accountable for overall TMF maintenance during the trial. Investigators are accountable for ISF completeness. QA is accountable for verifying inspection readiness.

Procedure

1. Protocol and Amendments
1.1 File final approved protocol and all subsequent amendments.
1.2 Ensure all amendments are approved by EC/IRB and regulatory authorities.

2. Informed Consent Documentation
2.1 File signed informed consent forms (ICFs) for each subject.
2.2 Ensure contemporaneous version control and language approvals.
2.3 Maintain ICF Filing Log (Annexure-1).

3. Investigator and Site Documentation
3.1 File updated CVs and training certificates of PI and site staff.
3.2 File updated Delegation of Authority Logs.
3.3 File Investigator communication with sponsor/CRO.

4. Monitoring Documentation
4.1 File monitoring visit reports, follow-up letters, and responses.
4.2 Ensure reconciliation between reports and trial activities.
4.3 Maintain Monitoring Report Log (Annexure-2).

5. Investigational Product Documentation
5.1 File IP accountability logs, receipts, dispensing records, and destruction logs.
5.2 File temperature logs and excursion reports.
5.3 Maintain IP Accountability Log (Annexure-3).

6. Safety Documentation
6.1 File SAE reports, SUSAR submissions, and follow-up documentation.
6.2 File DSUR/PSUR submissions and safety committee communications.
6.3 Maintain Safety Reporting Log (Annexure-4).

7. Subject-Level Documentation
7.1 File subject ID logs, screening and enrolment logs.
7.2 File eligibility verification checklists.
7.3 Maintain Subject Tracking Log (Annexure-5).

8. Correspondence and Communication
8.1 File essential correspondence with regulators, ECs/IRBs, CROs, and vendors.
8.2 File minutes of meetings and teleconferences.
8.3 Maintain Correspondence Log (Annexure-6).

9. Training and Qualification
9.1 File training records for staff joining during the trial.
9.2 Maintain GCP training certificates.
9.3 Maintain Training Record Log (Annexure-7).

10. Quality Control
10.1 Perform monthly QC checks on TMF/ISF.
10.2 Document findings in TMF QC Log (Annexure-8).
10.3 Correct discrepancies within 10 working days.

Abbreviations

• SOP: Standard Operating Procedure
• TMF/ISF: Trial Master File / Investigator Site File
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• EC/IRB: Ethics Committee / Institutional Review Board
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• DSUR/PSUR: Development Safety Update Report / Periodic Safety Update Report

Documents

1. ICF Filing Log (Annexure-1)
2. Monitoring Report Log (Annexure-2)
3. IP Accountability Log (Annexure-3)
4. Safety Reporting Log (Annexure-4)
5. Subject Tracking Log (Annexure-5)
6. Correspondence Log (Annexure-6)
7. Training Record Log (Annexure-7)
8. TMF QC Log (Annexure-8)

References

• ICH E6(R2/R3) – Essential Documents During Trial
• FDA – TMF Maintenance Guidance
• EMA – TMF and ISF Inspection Guidance
• CDSCO – Essential Documents Filing
• WHO – GCP Essential Documents

Version: 1.0

Approval Section

Annexures

Annexure-1: ICF Filing Log

Annexure-2: Monitoring Report Log

Annexure-3: IP Accountability Log

Annexure-4: Safety Reporting Log

Annexure-5: Subject Tracking Log

Annexure-6: Correspondence Log

Annexure-7: Training Record Log

Annexure-8: TMF QC Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Onsite-Monitoring-Visits-and-Source-Data-Verification”
},
“headline”: “SOP for Onsite Monitoring Visits and Source Data Verification”,
“description”: “This SOP describes procedures for conducting onsite monitoring visits and performing source data verification (SDV) in clinical trials, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP standards.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Onsite Monitoring Visits and Source Data Verification

Purpose

The purpose of this SOP is to define the standardized procedures for conducting onsite monitoring visits and performing Source Data Verification (SDV) in clinical trials. Onsite monitoring ensures participant safety, data integrity, compliance with the protocol, and adherence to ICH GCP, FDA, EMA, CDSCO, and WHO requirements.

Scope

This SOP applies to Clinical Research Associates (CRAs), sponsors, CROs, investigators, and QA personnel involved in trial oversight. It covers preparation, conduct, and follow-up of onsite monitoring visits, as well as verification of source data against Case Report Forms (CRFs) and electronic data capture (EDC) systems.

Responsibilities

• CRA/Monitor: Conducts onsite visits, performs SDV, and documents findings in monitoring reports.
• PI: Ensures site staff facilitate monitoring activities and provides access to source documents.
• Study Coordinator: Prepares essential documents and subject records for CRA review.
• Sponsor/CRO: Defines monitoring visit frequency and ensures timely follow-up on findings.
• QA Officer: Reviews monitoring documentation and audits selected visits.

Accountability

The sponsor is accountable for ensuring monitoring visits are planned and executed. The CRA is accountable for conducting SDV and documenting deviations or discrepancies. The PI is accountable for site compliance and implementation of corrective actions.

Procedure

1. Pre-Visit Preparation
CRA reviews protocol, Investigator Site File (ISF), prior monitoring reports, and site status.
Notify PI and study coordinator at least 2 weeks prior to visit.
Prepare Monitoring Visit Checklist (Annexure-1).

2. Conduct of Onsite Visit
Meet with PI and staff to review site progress and issues.
Verify informed consent process and ensure original signed forms are filed.
Review protocol compliance including visit schedules, dosing, and procedures.
Conduct Source Data Verification (SDV): compare CRF entries with source documents (lab reports, hospital records, AE/SAE notes).
Check drug accountability and investigational product (IP) storage conditions.
Review essential documents including delegation logs, training records, and regulatory binders.

3. Documentation During Visit
Record findings in Monitoring Visit Report (Annexure-2).
Document major deviations, missing data, or inconsistencies.
Discuss preliminary findings with PI at end of visit.

4. Post-Visit Activities
Submit monitoring report within 7 working days.
File report in TMF and ISF.
Ensure CAPA plans are initiated for deviations (Annexure-3).

5. Frequency of Visits
Conduct first monitoring visit within 4 weeks of first subject enrollment.
Subsequent visits scheduled based on enrollment rate, data volume, and risk profile (every 6–8 weeks or as defined in Monitoring Plan).

6. Escalation
Immediate escalation required for critical GCP violations or safety concerns.
Document escalations in Escalation Log (Annexure-4).

7. Archiving
Archive all monitoring visit reports, SDV checklists, CAPA documentation, and escalation logs in TMF.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CRO: Clinical Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• SDV: Source Data Verification
• IP: Investigational Product
• CAPA: Corrective and Preventive Action

Documents

1. Monitoring Visit Checklist (Annexure-1)
2. Monitoring Visit Report (Annexure-2)
3. CAPA Log (Annexure-3)
4. Escalation Log (Annexure-4)

References

• ICH E6(R2) – Good Clinical Practice
• FDA – Guidance on Risk-Based Monitoring
• EMA – Monitoring Clinical Trials
• CDSCO – Monitoring Requirements
• WHO – Onsite Monitoring Recommendations

Version: 1.0

Approval Section

Annexures

Annexure-1: Monitoring Visit Checklist

Annexure-2: Monitoring Visit Report

Annexure-3: CAPA Log

Annexure-4: Escalation Log

Revision History

For more SOPs visit: Pharma SOP